Insider Transactions in Q1 2022 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2022
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
146,388
-0.88%
|
$7,465,788
$51.7 P/Share
|
|
Feb 11
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
146,388
+3.36%
|
$731,940
$5.19 P/Share
|
|
Jan 07
2022
|
Marianne De Backer Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+21.48%
|
-
|
|
Jan 07
2022
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+12.96%
|
-
|
|
Jan 07
2022
|
Douglas B Given Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+5.22%
|
-
|
|
Jan 07
2022
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+36.06%
|
-
|
|
Jan 07
2022
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+6.51%
|
-
|
|
Jan 07
2022
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+16.6%
|
-
|
|
Jan 07
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,806
+0.29%
|
$59,030
$5.19 P/Share
|
|
Jan 05
2022
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
32,500
-1.76%
|
$2,015,000
$62.59 P/Share
|
|
Jan 05
2022
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
40,000
-2.04%
|
$2,480,000
$62.41 P/Share
|
|
Jan 05
2022
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
6,250
-0.78%
|
$387,500
$62.6 P/Share
|
|
Jan 04
2022
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
19,375
-2.21%
|
$1,298,125
$67.07 P/Share
|
|
Jan 03
2022
|
Michael S Perry Director |
SELL
Open market or private sale
|
Direct |
4,500
-1.69%
|
$292,500
$65.22 P/Share
|
|
Jan 03
2022
|
Marianne De Backer Director |
SELL
Open market or private sale
|
Direct |
4,500
-7.44%
|
$292,500
$65.17 P/Share
|
|
Jan 03
2022
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
4,050
-17.55%
|
$263,250
$65.18 P/Share
|
|
Jan 03
2022
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
4,500
-5.18%
|
$292,500
$65.16 P/Share
|
|
Jan 01
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+16.51%
|
-
|
|
Jan 01
2022
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+10.64%
|
-
|
|
Jan 01
2022
|
James C Hamilton Chief Discovery/Trans Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+23.28%
|
-
|
|
Jan 01
2022
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+13.59%
|
-
|